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Abstract 
The short QT syndrome (SQTS) is a recently identified 
genetic disorder associated with ventricular and/or atrial 
arrhythmias and increased risk of sudden cardiac death. 
The SQTS variant 1 (SQT1) N588K mutation to the hERG 
gene causes a gain-of-function to IKr which shortens the 
ventricular effective refractory period (ERP), as well as 
reducing the potency of several drugs which block the 
hERG channel. This study used computational modelling 
to assess the effects of disopyramide (DISO), a class 1a 
anti-arrhythmic agent, on human ventricular electro-
physiology in SQT1. 
The O’Hara Rudy dynamic (ORd) model of the human 
ventricle action potential (AP) was modified to 
incorporate a Markov chain model of IKr/hERG including 
formulations for wild type (WT) and SQT1 N588K mutant 
hERG channels. The blocking effects of DISO on IKr, INa, 
ICaL, and Ito were modelled using IC50 and Hill coefficient 
values from the literature. The ability of DISO to prolong 
the QT interval was evaluated using a 1D model of 
human ventricular cells with transmural heterogeneities 
and the corresponding pseudo-ECG. 
At a clinically-relevant concentration of 10 µM DISO, 
the action potential duration (APD) at the single cell level 
was increased significantly through inhibition of mutant 
SQT1-hERG channels. The corrected QT interval in 
tissue was prolonged. This study provides further 
evidence that DISO is a suitable treatment for hERG-
mediated SQTS. 
1. Introduction
The short QT syndrome (SQTS) refers to a genetic 
condition of the heart in which the QT interval on the 
ECG is abnormally short, which leads to an increased risk 
of cardiac arrhythmias and sudden cardiac death (SCD) 
[1]. The first identified form of the SQTS (SQT1) was 
found to be caused by a missense mutation (N588K) to 
the human Ether-à-go-go-Related Gene (hERG), which 
encodes the α subunit of the cardiac rapid delayed 
rectifier potassium current, IKr [2]. The N588K-hERG 
channel mutation causes a gain-of-function to IKr through 
severely impaired inactivation over the physiological 
range of membrane potentials [3]. In a prior 
computational study from our group, this was shown to 
profoundly reduce ventricular effective refractory period 
(ERP), decreasing the minimal substrate size necessary to 
sustain re-entry and increasing the lifespan of re-entrant 
excitation waves [4]. Whereas multiple pro-
arrhythmogenic effects of SQT1 in the human ventricles 
have been extensively characterised, less is known about 
the pharmacology of SQT1. 
The current treatment for SQTS patients who show 
inducible ventricular tachycardia/fibrillation during 
programmed electrical stimulation is an implantable 
cardioverter-defibrillator (ICD) device [5]. However, 
such devices have a well-documented propensity to 
oversense T-waves (which often appear tall and peaked in 
SQTS patients) leading to erroneous identification of a 
tachyarrhythmic event, and are not particularly suitable 
for paediatric patients [6], necessitating the investigation 
of alternative, pharmacological  approaches.  
An in vitro study by McPate et al. [7] used whole-cell 
patch clamp measurements of IKr/hERG in Chinese hamster 
ovary cells at 37ºC to evaluate the blocking potency of 
the class 1a anti-arrhythmic drug disopyramide (DISO), 
where it was seen that N588K mutant hERG channels 
caused only a modest 1.5-fold increase in the IC50 (half 
maximal inhibitory concentration), less than the 3.5-fold 
increase seen in quinidine, a commonly used drug in the 
SQT1 setting [8]. The efficacy of DISO in SQT1 in vitro 
suggests that the drug does not require block of the 
inactivated state in order to exert its inhibitory effect. 
A pilot study showed that oral DISO restored both the 
QT interval and ventricular ERP in SQT1 patients in vivo, 
highlighting its potential use as an alternative to quinidine 
[9]. Here, an in silico approach was taken to gain 
mechanistic understanding into the action of DISO on 
human ventricular electrophysiology and consequent 
effects on QT interval prolongation.  
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2. Methods
2.1. Model development 
The O’Hara Rudy dynamic (ORd) model of the human 
ventricular action potential (AP) [10] was modified to 
include a previously-described Markov chain formulation 
of wild type (WT) and N588K mutant IKr/hERG, with 
kinetic changes accounting for impaired inactivation 
during the AP [11]. The gating scheme of the Markov 
chain model of the hERG channel is shown in Figure 1. 
Figure 1: A schematic diagram of the Markov chain 
model of IKr/hERG used in this study. C1-C3 corresponds to 
closed states, I is an inactivated state, and O is the open 
channel conducting state. Microscopic reversibility is 
ensured by setting μ = (αi∙β2/βi). 
The SQT1 phenotype was described using a 1:1 ratio 
of WT to mutant hERG channels, as the N588K mutation 
is expressed heterozygously in vivo. The conductance of 
IKr was chosen based on the APD prolongation observed 
under experimental IKr block in the human ventricles [12], 
and the conductances of IKs and IK1 adjusted accordingly. 
An IKr scaling factor ratio of 1.5:1 in epicardial (EPI) to 
endocardial (ENDO) cells, respectively, was applied as 
suggested in the study of Adeniran et al. [4], in order to 
generate a tall, symmetrical T-wave in the pseudo-ECG 
of the SQT1 phenotype, as seen clinically [2].  
The steady-state effects of the class 1a drug DISO on 
IKr, INa, ICaL, and Ito were described using IC50 and nH 
(Hill coefficient) values taken from the literature [7], [13], 
[14]. The fractional block of each ionic current affected 
by DISO was modelled using simple pore block theory 
[15], which postulates that the conductance gi of an ionic 
current type i is modified in a concentration-dependent 
manner such that 
𝑔𝑔𝑖𝑖 = 𝑔𝑔control,𝑖𝑖  11+([IC50]𝑖𝑖 [DISO])⁄ 𝑛𝑛𝑛𝑛,  (1) 
where [DISO] is the concentration of DISO and all other 
parameters retain their previous definitions. The blocking 
potency of DISO on WT/N588K IKr/hERG, INa, ICaL, and Ito 
currents from a concentration of 0.1 µM to 1000 µM is 
shown in Figure 2. 
2.2. Tissue simulations 
Propagation of APs in tissue was described using the 
monodomain equation 
𝜕𝜕𝑉𝑉m 𝜕𝜕𝜕𝜕⁄ =  ∇ ∙ 𝑫𝑫(∇𝑉𝑉m) − 𝐼𝐼ion 𝐶𝐶m⁄ , (2) 
where Vm is transmembrane potential, D is the diffusion 
coefficient tensor, Iion is the total ionic current, and Cm is 
the membrane capacitance. Eq (2) was discretised in 
space using the finite difference method and a spatial step 
of 0.15 mm.  
Figure 2: Dose-dependent effects of disopyramide 
(DISO) on IKr (WT and N588K mutant hERG channels 
shown separately), INa, ICaL, and Ito. 
The 1D transmural model of human ventricle had a 
size of 15 mm, comprising 25 ENDO, 35 MCELL, and 40 
EPI cells, with isotropic diffusion except for a 5-fold 
decrease in D at the MCELL:EPI border, as described in 
[4]. A stimulus was applied at the endocardial surface, 
eliciting a plane wave which propagated transmurally 
towards the epicardial surface. The pseudo-ECG was 
calculated using the method of Gima and Rudy [16], i.e. 
Φ(𝑥𝑥′) = 𝑎𝑎2
4
∫(−∇𝑉𝑉m) ∙ �∇ 1𝑟𝑟� 𝑑𝑑𝑥𝑥, (3) 
where Φ is a unipolar potential generated by the 1D 
transmural fibre, a is the radius of the fibre, and r is the 
distance from a source point x to the field point x’ 
recorded at a site located 2 cm away from the epicardial 
end of the strand. The QT interval was corrected 
according to Framingham’s QT correction formula. 
3. Results
3.1. Single cell investigations 
At the single cell level, all concentrations of DISO 
simulated (5 µM, 10 µM, 20 µM) caused prolongation of 
 
 
  
the APD in SQT1 conditions at a basic cycle length 
(BCL) of 850 ms, which roughly corresponds to 70 bpm 
(Figure 3Ai). The prolongation in APD was found to be 
predominantly due to the blocking actions of DISO on 
hERG channel IKr currents (Figure 3Aii), with minimal 
changes in the APD resulting from block of other currents 
(not shown).  
At a concentration of 10 µM, the fractional block due 
to DISO on affected ionic currents was as follows (in 
descending order): WT IKr/hERG (48.3%), N588K IKr/hERG 
(42.9%), INa (4.4%), Ito (3.0%), and ICaL (1.0%) Changes 
to the APD90 and peak IKr current density due to varying 
concentrations of DISO are summarised in Figure 3B, 
where it can be seen that both changed in a concentration-
dependent manner. 
Figure 3: Effects of varying concentrations of DISO (5 
µM, 10 µM, 20 µM) on human ventricular endocardial 
(ENDO) AP waveforms and APD90 (Ai,Aii), and IKr 
current profile/peak density (Bi,Bii) in SQT1 conditions. 
The drug-free SQT1 AP and characteristics are shown in 
blue. BCL = 850 ms.  
3.2. 1D simulations 
 The 1D transmural ventricular strand model was also 
paced at a BCL of 850 ms, using the aforementioned 
protocol. Space-time plots of AP propagation in the 1D 
strand are shown in Figure 4. The distribution of the 
membrane potential across the 1D transmural strand is 
shown using a standard rainbow palette, ranging from 
−85 to +35 mV. The pseudo-ECG was computed in SQT1 
conditions, and under application of 10 µM DISO. A 
concentration of 10 µM DISO prolonged the corrected 
QT interval from 263 ms to 338 ms.  
4. Discussion
A biophysically-detailed Markov chain formulation of 
the SQT1 phenotype [11] has been incorporated into an 
established model of the human ventricular action 
potential incorporating transmural heterogeneities [10]. 
The resulting model has been used to investigate the 
functional consequences of the class 1a anti-arrhythmic 
agent disopyramide (DISO) on drug-induced APD and 
QT interval prolongation. 
The therapeutic steady-state plasma levels of DISO are 
reported to be ~2.8-4.4 mg/L [17], which corresponds to a 
dose of ~8.3-13.0 µM. Several doses (5 µM, 10 µM, 20 
µM) were simulated in order to cover a range of 
possibilities, including low and high doses. 
Our simulation results showed that combined blocking 
effects of DISO on IKr, INa, ICaL, and Ito caused significant 
prolongation of the action potential duration (APD). At a 
clinically-relevant concentration the IKr current was 
affected the most (even factoring in reduced blocking 
potency in SQT1-related N588K mutant hERG channels), 
with a smaller degree of INa/Ito block and almost 
negligible block of ICaL. In the 1D transmural ventricular 
strand model, a concentration of 10 µM produced a 
significant prolongation of the QT interval, bringing it 
much closer to the normal range of QT intervals. This is 
consistent with findings from the pilot study of Schimpf 
et al. [9], in which oral DISO successfully prolonged the 
QT interval and ventricular ERP in vivo.  
Figure 4: Dose-dependent effects of DISO on the pseudo-
ECG of a 1D transmural strand of human ventricular 
tissue in SQT1 conditions (A), with corresponding QTc 
intervals (B) as calculated using Framingham’s QT 
correction formula. BCL = 850 ms. 
Reduced ERP due to N588K mutant hERG channels in 
the human ventricles was shown to be an important factor 
 
 
  
in increasing susceptibility to re-entrant arrhythmias in a 
study by Adeniran et al. [4]. The APD prolongation due 
to application of DISO is likely to partially/fully restore 
the ERP, de-stabilising re-entrant circuits in tissue and 
increasing likelihood of arrhythmia termination.  
5. Conclusion
As the SQTS is very rare, extensive clinical trials are 
currently not feasible. However, computational modelling 
can be a powerful tool in assessing drug-induced 
APD/QT interval prolongation, as well as helping to 
dissect underlying ionic mechanisms. In the present 
study, we have demonstrated that the class 1a anti-
arrhythmic agent disopyramide is an effective inhibitor of 
mutant hERG channels associated with SQT1 in the 
human ventricles. This study provides new insights into a 
potential pharmacological option in the treatment of 
SQT1 and other hERG-mediated forms of SQTS. 
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